Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions

Guido Martignoni, Stefano Gobbo, Philippe Camparo, Matteo Brunelli, Enrico Munari, Diego Segala, Maurizio Pea, Franco Bonetti, Peter B Illei, Georges J. Netto, Marc Ladanyi, Marco Chilosi, Pedram Argani

Research output: Contribution to journalArticle

Abstract

Cathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts. TFE3 and TFEB are members of the same transcription factor subfamily as MITF and all three have overlapping transcriptional targets. We have shown that all t(6;11) renal cell carcinomas, which harbor an Alpha-TFEB gene fusion, as well as a subset of the Xp11 translocation renal carcinomas, which harbor various TFE3 gene fusions, express cathepsin K, while no other common renal carcinoma does. We have hypothesized that overexpression of TFEB or certain TFE3 fusion proteins function like MITF in these neoplasms, and thus activate cathepsin K expression. However, the expression of cathepsin K in specific genetic subtypes of Xp11 translocation carcinomas, as well as alveolar soft part sarcoma, which harbors the same ASPSCR1-TFE3 gene fusion as some Xp11 translocation carcinomas, has not been addressed. We performed immunohistochemistry for cathepsin K on 14 genetically confirmed t(X;1)(p11;q21) carcinomas, harboring the PRCC-TFE3 gene fusion; eight genetically confirmed t(X;17)(p11;q25) carcinomas, harboring the ASPSCR1-TFE3 gene fusion; and 18 alveolar soft part sarcomas (12 genetically confirmed), harboring the identical ASPSCR1-TFE3 gene fusion. All 18 alveolar soft part sarcomas expressed cathepsin K. In contrast, all eight ASPSCR1-TFE3 carcinomas were completely negative for cathepsin K. However, 12 of 14 PRCC-TFE3 carcinomas expressed cathepsin K. Expression of cathepsin K distinguishes alveolar soft part sarcoma from the ASPSCR1-TFE3 carcinoma, harboring the same gene fusion. The latter can be useful diagnostically, especially when alveolar soft part sarcoma presents in an unusual site (such as bone) or with clear cell morphology, which raises the differential diagnosis of metastatic ASPSCR1-TFE3 renal cell carcinoma. The difference in expression of cathepsin K between the PRCC-TFE3 and ASPSCR1-TFE3 carcinomas, together with the observed clinical differences between these subtypes of Xp11 translocation carcinomas, suggests the possibility of functional differences between these two related fusion proteins.

Original languageEnglish (US)
Pages (from-to)1313-1319
Number of pages7
JournalModern Pathology
Volume24
Issue number10
DOIs
StatePublished - Oct 2011

Fingerprint

Cathepsin K
Gene Fusion
Alveolar Soft Part Sarcoma
Carcinoma
Neoplasms
Microphthalmia-Associated Transcription Factor
Renal Cell Carcinoma
Kidney
Osteoclasts
Proteins
Differential Diagnosis
Peptide Hydrolases
Transcription Factors

Keywords

  • alveolar soft part sarcoma
  • cathepsin K
  • renal
  • TFE/MITF
  • TFE3
  • translocation carcinoma
  • Xp11

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Martignoni, G., Gobbo, S., Camparo, P., Brunelli, M., Munari, E., Segala, D., ... Argani, P. (2011). Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern Pathology, 24(10), 1313-1319. https://doi.org/10.1038/modpathol.2011.93

Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. / Martignoni, Guido; Gobbo, Stefano; Camparo, Philippe; Brunelli, Matteo; Munari, Enrico; Segala, Diego; Pea, Maurizio; Bonetti, Franco; Illei, Peter B; Netto, Georges J.; Ladanyi, Marc; Chilosi, Marco; Argani, Pedram.

In: Modern Pathology, Vol. 24, No. 10, 10.2011, p. 1313-1319.

Research output: Contribution to journalArticle

Martignoni, G, Gobbo, S, Camparo, P, Brunelli, M, Munari, E, Segala, D, Pea, M, Bonetti, F, Illei, PB, Netto, GJ, Ladanyi, M, Chilosi, M & Argani, P 2011, 'Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions', Modern Pathology, vol. 24, no. 10, pp. 1313-1319. https://doi.org/10.1038/modpathol.2011.93
Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern Pathology. 2011 Oct;24(10):1313-1319. https://doi.org/10.1038/modpathol.2011.93
Martignoni, Guido ; Gobbo, Stefano ; Camparo, Philippe ; Brunelli, Matteo ; Munari, Enrico ; Segala, Diego ; Pea, Maurizio ; Bonetti, Franco ; Illei, Peter B ; Netto, Georges J. ; Ladanyi, Marc ; Chilosi, Marco ; Argani, Pedram. / Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. In: Modern Pathology. 2011 ; Vol. 24, No. 10. pp. 1313-1319.
@article{4aa1ba300a0d4926bd094837d77052b4,
title = "Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions",
abstract = "Cathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts. TFE3 and TFEB are members of the same transcription factor subfamily as MITF and all three have overlapping transcriptional targets. We have shown that all t(6;11) renal cell carcinomas, which harbor an Alpha-TFEB gene fusion, as well as a subset of the Xp11 translocation renal carcinomas, which harbor various TFE3 gene fusions, express cathepsin K, while no other common renal carcinoma does. We have hypothesized that overexpression of TFEB or certain TFE3 fusion proteins function like MITF in these neoplasms, and thus activate cathepsin K expression. However, the expression of cathepsin K in specific genetic subtypes of Xp11 translocation carcinomas, as well as alveolar soft part sarcoma, which harbors the same ASPSCR1-TFE3 gene fusion as some Xp11 translocation carcinomas, has not been addressed. We performed immunohistochemistry for cathepsin K on 14 genetically confirmed t(X;1)(p11;q21) carcinomas, harboring the PRCC-TFE3 gene fusion; eight genetically confirmed t(X;17)(p11;q25) carcinomas, harboring the ASPSCR1-TFE3 gene fusion; and 18 alveolar soft part sarcomas (12 genetically confirmed), harboring the identical ASPSCR1-TFE3 gene fusion. All 18 alveolar soft part sarcomas expressed cathepsin K. In contrast, all eight ASPSCR1-TFE3 carcinomas were completely negative for cathepsin K. However, 12 of 14 PRCC-TFE3 carcinomas expressed cathepsin K. Expression of cathepsin K distinguishes alveolar soft part sarcoma from the ASPSCR1-TFE3 carcinoma, harboring the same gene fusion. The latter can be useful diagnostically, especially when alveolar soft part sarcoma presents in an unusual site (such as bone) or with clear cell morphology, which raises the differential diagnosis of metastatic ASPSCR1-TFE3 renal cell carcinoma. The difference in expression of cathepsin K between the PRCC-TFE3 and ASPSCR1-TFE3 carcinomas, together with the observed clinical differences between these subtypes of Xp11 translocation carcinomas, suggests the possibility of functional differences between these two related fusion proteins.",
keywords = "alveolar soft part sarcoma, cathepsin K, renal, TFE/MITF, TFE3, translocation carcinoma, Xp11",
author = "Guido Martignoni and Stefano Gobbo and Philippe Camparo and Matteo Brunelli and Enrico Munari and Diego Segala and Maurizio Pea and Franco Bonetti and Illei, {Peter B} and Netto, {Georges J.} and Marc Ladanyi and Marco Chilosi and Pedram Argani",
year = "2011",
month = "10",
doi = "10.1038/modpathol.2011.93",
language = "English (US)",
volume = "24",
pages = "1313--1319",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions

AU - Martignoni, Guido

AU - Gobbo, Stefano

AU - Camparo, Philippe

AU - Brunelli, Matteo

AU - Munari, Enrico

AU - Segala, Diego

AU - Pea, Maurizio

AU - Bonetti, Franco

AU - Illei, Peter B

AU - Netto, Georges J.

AU - Ladanyi, Marc

AU - Chilosi, Marco

AU - Argani, Pedram

PY - 2011/10

Y1 - 2011/10

N2 - Cathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts. TFE3 and TFEB are members of the same transcription factor subfamily as MITF and all three have overlapping transcriptional targets. We have shown that all t(6;11) renal cell carcinomas, which harbor an Alpha-TFEB gene fusion, as well as a subset of the Xp11 translocation renal carcinomas, which harbor various TFE3 gene fusions, express cathepsin K, while no other common renal carcinoma does. We have hypothesized that overexpression of TFEB or certain TFE3 fusion proteins function like MITF in these neoplasms, and thus activate cathepsin K expression. However, the expression of cathepsin K in specific genetic subtypes of Xp11 translocation carcinomas, as well as alveolar soft part sarcoma, which harbors the same ASPSCR1-TFE3 gene fusion as some Xp11 translocation carcinomas, has not been addressed. We performed immunohistochemistry for cathepsin K on 14 genetically confirmed t(X;1)(p11;q21) carcinomas, harboring the PRCC-TFE3 gene fusion; eight genetically confirmed t(X;17)(p11;q25) carcinomas, harboring the ASPSCR1-TFE3 gene fusion; and 18 alveolar soft part sarcomas (12 genetically confirmed), harboring the identical ASPSCR1-TFE3 gene fusion. All 18 alveolar soft part sarcomas expressed cathepsin K. In contrast, all eight ASPSCR1-TFE3 carcinomas were completely negative for cathepsin K. However, 12 of 14 PRCC-TFE3 carcinomas expressed cathepsin K. Expression of cathepsin K distinguishes alveolar soft part sarcoma from the ASPSCR1-TFE3 carcinoma, harboring the same gene fusion. The latter can be useful diagnostically, especially when alveolar soft part sarcoma presents in an unusual site (such as bone) or with clear cell morphology, which raises the differential diagnosis of metastatic ASPSCR1-TFE3 renal cell carcinoma. The difference in expression of cathepsin K between the PRCC-TFE3 and ASPSCR1-TFE3 carcinomas, together with the observed clinical differences between these subtypes of Xp11 translocation carcinomas, suggests the possibility of functional differences between these two related fusion proteins.

AB - Cathepsin K is a protease whose expression is driven by microphthalmia transcription factor (MITF) in osteoclasts. TFE3 and TFEB are members of the same transcription factor subfamily as MITF and all three have overlapping transcriptional targets. We have shown that all t(6;11) renal cell carcinomas, which harbor an Alpha-TFEB gene fusion, as well as a subset of the Xp11 translocation renal carcinomas, which harbor various TFE3 gene fusions, express cathepsin K, while no other common renal carcinoma does. We have hypothesized that overexpression of TFEB or certain TFE3 fusion proteins function like MITF in these neoplasms, and thus activate cathepsin K expression. However, the expression of cathepsin K in specific genetic subtypes of Xp11 translocation carcinomas, as well as alveolar soft part sarcoma, which harbors the same ASPSCR1-TFE3 gene fusion as some Xp11 translocation carcinomas, has not been addressed. We performed immunohistochemistry for cathepsin K on 14 genetically confirmed t(X;1)(p11;q21) carcinomas, harboring the PRCC-TFE3 gene fusion; eight genetically confirmed t(X;17)(p11;q25) carcinomas, harboring the ASPSCR1-TFE3 gene fusion; and 18 alveolar soft part sarcomas (12 genetically confirmed), harboring the identical ASPSCR1-TFE3 gene fusion. All 18 alveolar soft part sarcomas expressed cathepsin K. In contrast, all eight ASPSCR1-TFE3 carcinomas were completely negative for cathepsin K. However, 12 of 14 PRCC-TFE3 carcinomas expressed cathepsin K. Expression of cathepsin K distinguishes alveolar soft part sarcoma from the ASPSCR1-TFE3 carcinoma, harboring the same gene fusion. The latter can be useful diagnostically, especially when alveolar soft part sarcoma presents in an unusual site (such as bone) or with clear cell morphology, which raises the differential diagnosis of metastatic ASPSCR1-TFE3 renal cell carcinoma. The difference in expression of cathepsin K between the PRCC-TFE3 and ASPSCR1-TFE3 carcinomas, together with the observed clinical differences between these subtypes of Xp11 translocation carcinomas, suggests the possibility of functional differences between these two related fusion proteins.

KW - alveolar soft part sarcoma

KW - cathepsin K

KW - renal

KW - TFE/MITF

KW - TFE3

KW - translocation carcinoma

KW - Xp11

UR - http://www.scopus.com/inward/record.url?scp=80053563153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053563153&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2011.93

DO - 10.1038/modpathol.2011.93

M3 - Article

VL - 24

SP - 1313

EP - 1319

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 10

ER -